pharmaphorum5h
BMS extends its cost-cutting drive by another $2bn
BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics towards the end of 2023, and analysts at ...
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, leading with tecarfarin, a new Vitamin K ...
Targeted Oncology1d
Selection of Next-Gen BTK in CLL Limited By Lack of Direct Comparison
During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK ...
Bristol-Myers Squibb's SWOT analysis: stock outlook mixed amid pipeline progress
Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical giant with a market capitalization of $120.8 billion, finds ...
Healio3d
Stool DNA testing ‘can be performed safely’ regardless of anticoagulant, antiplatelet use
Oral anticoagulant or antiplatelet medication use had no substantial effect on the accuracy of multitarget stool DNA testing for colorectal cancer, according to a study published in Gastro Hep ...